Polyvalent type IV sensitizations to multiple fragrances and a skin protection cream in a metal worker.

Fragrances are very common in everyday products. A metalworker with chronic hand eczema and previously diagnosed type IV sensitizations to epoxy resin, balsam of Peru, fragrance mix and fragrance mix II was diagnosed with additional type IV sensitizations to geraniol, hydroxycitronellal, lilial, tree moss, oak moss absolute, citral, citronellol, farnesol, Lyral, fragrance mix II and fragrance mix (with sorbitan sesquioleate). In addition, a type IV sensitization to the skin protection cream containing geraniol and citronellol used at the workplace was detected, and deemed occupationally relevant in this case. The patient could have had contact to fragrances through private use of cosmetics and detergents. On the other hand, the fragrance-containing skin protection cream supports occupational exposure. This case report demonstrates that fragrance contact allergy has to be searched for and clarified individually, which requires a thorough history and a detailed analysis of the work place.

Is nickel allergy an occupational disease? Discussion of the occupational relevance of a type IV allergy to nickel (II) sulfate using case reports.

Type IV sensitization to nickel (II) sulfate is common in the general population. Nickel can be found in different metals leading to occupational exposition in industrial professions. The individual clinical relevance of nickel allergy can easily be identified but it can be difficult to assess if nickel allergy was acquired privately or occupationally. The problem if nickel allergy fulfills the criteria of an occupational skin disease is presented in three case reports. The occupational relevance of a type IV sensitization to nickel in a chemical laboratory assistant, a flight attendant and a cashier are discussed. Important conditions for acquiring nickel allergy are contact with nickel-plated and nickel-releasing materials, the kind of skin contact, the status of the epidermal barrier, and the individual working conditions with an increased bioavailability of nickel. In cases of type IV sensitization to nickel, the affected person cannot continue to work in metal plating or with contact to nickel-plated metals. The causal relationship between the type IV sensitization to nickel and the occupation needs to be clarified in each individual case. In general, occupationally caused nickel allergy is rare and the occupational relevance of nickel allergy is often overestimated.

Response of refractory colitis to intravenous or oral tacrolimus (FK506).

Intravenous cyclosporine has proven to be an alternative to emergency colectomy in steroid-refractory ulcerative colitis, whereas the experience with FK506 is limited. In this report we compare intravenous to oral FK506 treatment in 38 patients with refractory ulcerative (n = 33) or indeterminate (n = 5) colitis. FK506 was started intravenously in the first group (n = 18) at a dose of 0.01 to 0.02 mg/kg up to 14 days, followed by 0.1 to 0.2 mg/kg orally, or was started orally at this dose in a second group (n = 20). Additional azathioprine/6-mercaptopurine was given and steroids were tapered in responding patients, followed by a dose reduction of FK506. Clinical disease activity and laboratory parameters were assessed to evaluate efficacy and safety. Primary objectives were the induction of remission (Truelove index of mild) and colectomy-free survival. Treatment lasted for a mean of 7.6 months, and the mean observation period was 16.2 months. Eighteen of 38 patients improved within 14 days, and a complete remission was achieved in 13 patients after 1 month. A colectomy within 1 month was performed in 3 of 38 patients. The overall colectomy rate was 34%. One-half of the patients with a minimum follow-up of 2 years required a colectomy. Intravenous and per oral administration were equally safe and effective. The most frequent adverse events included tremor, hyperglycemia, hypertension, and infection, but none were severe. Renal impairment was rare and subsided upon drug withdrawal. In conclusion. FK506 is effective in the treatment of refractory colitis with per oral dosing being equivalent to intravenous administration.